Followers | 504 |
Posts | 10140 |
Boards Moderated | 0 |
Alias Born | 04/28/2014 |
Monday, December 14, 2015 11:39:14 AM
bullish 3.532
inverted head and shoulders
moving average breakout
## source: finance.yahoo.com
Mon, 14 Dec 2015 08:59:00 GMT ~ 3:59 am MediciNova reports positive interim safety and clinical outcomes data from clinical trial of MN-166
read full: http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#mnov
*********************************************************
Sun, 13 Dec 2015 23:10:08 GMT ~ MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
[at noodls] - , (GLOBE NEWSWIRE) -- , a biopharmaceutical company traded on the (NASDAQ:MNOV) and the JASDAQ Market of the (Code Number:4875), announced that principal investigator Dr. , Director, Neuromuscular/ALS-MDA ...
read full: http://www.noodls.com/view/058AA174BC313F7BD0D383FC78954FB6C16B8524
*********************************************************
Sun, 13 Dec 2015 23:00:00 GMT ~ MediciNova Announces Positive Interim Safety and Clinical Outcomes Data From Clinical Trial of MN-166 (ibudilast) in ALS Presented at the 26th International Symposium on ALS/MND in Orlando, FL
[GlobeNewswire] - LA JOLLA, Calif., Dec. 13, 2015-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that principal investigator ...
read full: http://finance.yahoo.com/news/medicinova-announces-positive-interim-safety-230000214.html
*********************************************************
Wed, 09 Dec 2015 22:44:03 GMT ~ MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
[at noodls] - MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting...
read full: http://www.noodls.com/view/6DB43E3D7B5CD8C01DCA3964BF96FB2673C95EFF
*********************************************************
Wed, 09 Dec 2015 22:30:00 GMT ~ MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting
[GlobeNewswire] - LA JOLLA, Calif., Dec. 09, 2015-- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange, announced that Dr. Daniel Roche today ...
read full: http://finance.yahoo.com/news/medicinova-announces-positive-findings-clinical-223000485.html
*********************************************************
$MNOV charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$MNOV company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/MNOV/company-info
Ticker: $MNOV
OTC Market Place: Not Available
CIK code: 0001226616
Company name: Medicinova, Inc.
Incorporated In: DE, USA
Business Description:
$MNOV share structure
## source: otcmarkets.com
Market Value: $104,248,603 a/o Dec 11, 2015
Shares Outstanding: 29,956,495 a/o Oct 23, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.001
$MNOV extra dd links
Company name: Medicinova, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=MNOV+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=MNOV+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=MNOV+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/news - http://finance.yahoo.com/q/h?s=MNOV+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/MNOV/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=MNOV+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/MNOV
DTCC (dtcc.com): http://search2.dtcc.com/?q=Medicinova%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Medicinova%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Medicinova%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/MNOV
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001226616&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=MNOV&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=MNOV
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=MNOV+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=MNOV+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=MNOV
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=MNOV
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=MNOV+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/MNOV/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=MNOV+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/MNOV.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=MNOV
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/MNOV/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/MNOV/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/MNOV
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/MNOV
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/MNOV:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=MNOV
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=MNOV
$MNOV DD Notes ~ http://www.ddnotesmaker.com/MNOV
Recent MNOV News
- MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND • GlobeNewswire Inc. • 09/09/2024 11:00:00 PM
- MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting • GlobeNewswire Inc. • 09/03/2024 11:00:00 PM
- MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition • GlobeNewswire Inc. • 08/29/2024 11:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/08/2024 08:32:00 PM
- MediciNova Chief Business Officer David H. Crean, Ph.D. Assumes Communications Role Overseeing Investor Engagement and Public Relations • GlobeNewswire Inc. • 06/20/2024 10:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:41:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/12/2024 11:40:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:15:10 PM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer • GlobeNewswire Inc. • 06/05/2024 10:00:00 AM
- MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024 • GlobeNewswire Inc. • 06/03/2024 10:00:00 AM
- MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions • GlobeNewswire Inc. • 05/28/2024 10:00:00 AM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer • GlobeNewswire Inc. • 05/20/2024 10:00:00 AM
- MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome • GlobeNewswire Inc. • 05/14/2024 10:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:15:29 PM
- MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast) • GlobeNewswire Inc. • 05/07/2024 10:00:00 AM
- MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO) • GlobeNewswire Inc. • 04/02/2024 11:00:00 PM
- MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan • GlobeNewswire Inc. • 03/26/2024 11:00:00 PM
- MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society • GlobeNewswire Inc. • 03/20/2024 11:00:00 PM
- MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology • GlobeNewswire Inc. • 03/12/2024 10:30:00 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/15/2024 09:25:31 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:27:28 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:25:25 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:23:50 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 01/19/2024 09:21:57 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM